Previous 10 | Next 10 |
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021 PR Newswire BOSTON , A...
Penny stocks are well-known for their high risk and potential for high reward. Because of that, many advisors suggest that this type of investment only take a small portion of your overall holdings. Some top financial firms have a rule of thumb that 10% or less is a good benchmark for high-...
NeuroBo Pharmaceuticals (NRBO) perks up 6% premarket after receiving approval of an amendment to its Contingent Value Rights ((CVR)) agreement from a majority of CVR holders. The CVRs were distributed to the holders of Gemphire Therapeutics (GEMP) common stock on December 30, 2019, ...
Hall of Fame Resort & Entertainment Company (HOFV) +71% after NFT deal.Dolphin Entertainment (DLPN) +66% after NFT deal.Alithya Group (ALYA) +52% on acquisition of R3D ConseilColor Star Technology (CSCW) +41%.Aptose Biosciences (APTO) +39% on Q4 results.Cinedigm C...
NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene Gemcabene to be Studied as a Stand-alone Treatment for COVID-19 and in Combination with Lead Asset, ANA001 PR Newswire BOSTON , March 24, 2021 /PRNewswire/ -- N...
NeuroBo Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference PR Newswire BOSTON , March 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that Company...
NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement PR Newswire BOSTON , Jan. 21, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced pri...
Gainers: Aclaris Therapeutics (ACRS) +184%.Gritstone Oncology (GRTS) +111%.Gevo (GEVO) +76%.Senseonics (SENS) +72%.TransEnterix (TRXC) +62%.Dare Bioscience (DARE) +57%.ENDRA Life Sciences (NDRA) +41%.Pennsylvania Real Estate Investment Trust (PEI) +41%.Tenax Therapeutics (TENX)...
NeuroBo Pharmaceuticals (NRBO) to raise $10M through the private placement of 2.5M common shares and warrants to purchase up to 2.5M shares at $4/share.Closing date is January 21. The five and one-half years warrants have an exercise price of $6.03/share/ Net proceeds will be used for working...
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement PR Newswire BOSTON , Jan. 19, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has entered into securities purc...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...